1 Berry Technology Solutions, Inc., Peachtree City, GA, United States. Electronic address: firstname.lastname@example.org.
2 IHRC, Inc., Atlanta, GA, United States. Electronic address: email@example.com.
3 Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, GA, United States. Electronic address: firstname.lastname@example.org.
4 Communicable Disease Program, Chicago Department of Public Health, Chicago, IL, United States. Electronic address: email@example.com.
5 Division of Immunization, Michigan Department of Health & Human Services, Lansing, MI, United States. Electronic address: firstname.lastname@example.org.
6 Infectious Disease Prevention and Health Services Bureau, Prevention and Health Promotion Administration, Maryland Department of Health, Baltimore, MD, United States. Electronic address: email@example.com.
7 Immunization Services Division, NCIRD, CDC and Adult Immunization Unit, New York City Department of Health and Mental Hygiene, New York, NY, United States. Electronic address: firstname.lastname@example.org.
8 Public Health Division, Oregon Health Authority, Portland, OR, United States. Electronic address: Judith.email@example.com.
9 San Antonio Metropolitan Health District, San Antonio, TX, United States. Electronic address: firstname.lastname@example.org.
10 Cherokee Nation Assurance, Atlanta, GA, United States. Electronic address: email@example.com.
11 Immunization Services Division, NCIRD, CDC, Atlanta, GA, United States. Electronic address: firstname.lastname@example.org.
Acute hepatitis B virus (HBV) infections in the United States occur predominantly among persons aged 30-59?years. The Centers for Disease Control and Prevention (CDC) recommends vaccination of adults at increased risk for HBV infection. Completing the hepatitis B (HepB) vaccine dose-series is critical for optimal immune response.
CDC funded 14 health departments (awardees) from 2012 to 2015 to implement a pilot HepB vaccination program for high-risk adults. We evaluated the pilot program to assess vaccine utilization; vaccine dose-series completion, including by vaccination location type; and implementation challenges.
Awardees collaborated with sites providing health care to persons at increased risk for HBV infection. Awardees collected information on doses administered, vaccine dose-series completion, and challenges completing and tracking vaccinations, including use of immunization information systems (IIS). Data were reported by each awardee in aggregate to CDC.
Six of 14 awardees administered 47,911 doses and were able to report patient-level dose-series completion. Among persons who received dose 1, 40.4% received dose 2, and 22.3% received dose 3. Local health department clinics had the highest 3-dose-series completion, 60.6% (531/876), followed by federally qualified health centers at 38.0% (923/2432). While sexually transmitted diseases (STD) clinics administered the most doses in total (17,173 [35.8% of 47,911 doses]), 3-dose-series completion was low (17.1%). The 14 awardees reported challenges regarding completing and tracking dose-series, including reaching high-risk adults for follow-up and inconsistencies in use of IIS or other tracking systems across sites.
Dose-series completion was low in all settings, but lowest where patients may be less likely to return for follow-up (e.g., STD clinics). Routinely assessing HepB vaccination needs of high-risk adults, including through use of IIS where available, may facilitate HepB vaccine dose-series completion.